TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
With
ReMuS Registry
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants starting with natalizumab after 1st January 2019 and participating in the ReMuS will be included in this study
You may not be if
Not Applicable (NA)
Clareo Health | TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
